Future studies should investigate whether persistent A3B upregulation in post-COVID-19 patients contributes to an increased risk of malignancy and whether targeting A3B activity could serve as a potential therapeutic intervention in severe COVID-19 patients. Here, APOBEC3B is linked to COVID-19.